研究单位：[1]Jiangsu HengRui Medicine Co., Ltd.[2]Beijing Anzhen Hospital[3]Gansu Provincial Hospital,Lanzhou,Gansu,China[4]Tongji Hospital,Wuhan,Hubei,China,430030[5]The Second Xiangya Hospital of Central South University,Changsha,Hunan,China[6]The Third Xiangya Hospital of Central South University,Changsha,Hunan,China[7]Northern Jiangsu People's Hospital,Yangzhou,Jiangsu,China,225001[8]Shengjing Hospital of China Medical University,Shenyang,Liaoning,China,110004[9]The First Affiliated Hospital of College of Medicine, Zhejiang University,Hangzhou,Zhejiang,China[10]Taizhou Hospital,Taizhou,Zhejiang,China[11]Beijing ANZHEN Hospital,Beijing,China,100029[12]China-Japan Friendship Hospital,Beijing,China,100029[13]Xuan Wu Hospital affiliated to Capital Medical University,Beijing,China,100053[14]Beijing Tongren hospital affiliated to Capital Medical University,Beijing,China
研究目的：
The aim of present study is to evaluate the efficacy and safety of Extended-Release Carvedilol Sulfate versus Sustained-release Metoprolol Succinate in Patients With Mild or Moderate Chronic Heart Failure.
